Shana Kelley, CTRL Therapeutics founder and chief technology officer
April 10, 2023 11:04 AM EDTUpdated 11:20 AM
Financing
Startups
Cell/Gene Tx

A new cell ther­a­py biotech emerges to find sol­id tu­mor-killing im­mune cells in pa­tients' blood

Kyle LaHucik

Senior Reporter

A new au­tol­o­gous cell ther­a­py mak­er is com­ing to the fore with $10 mil­lion to start.

Chica­go-based CTRL Ther­a­peu­tics hopes to ex­pand be­yond the cur­rent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times